Mirae Asset Global Investments
CADL icon

Mirae Asset Global Investments’s Candel Therapeutics CADL Stock Holding History

Mirae Asset Global Investments’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Sell
3,277
-544
-14% -$4.11K ﹤0.01% 1416
2026
Q1 		$18.7K Buy
3,821
+1,153
+43% +$6.28K ﹤0.01% 1440
2025
Q4 		$15.1K Buy
+2,668
New +$14.4K ﹤0.01% 1569

Other funds holding CADL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Mirae Asset Global Investments's CADL Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Candel Therapeutics (CADL) stake by 14% in Q2 2026, selling an estimated $4.11K and leaving 3,277 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

Mirae Asset Global Investments first reported a position in CADL in Q4 2025 and has held it in 3 quarters since. 46 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Mirae Asset Global Investments held 3,277 shares of Candel Therapeutics worth $33.8K as of Q2 2026.
  • Mirae Asset Global Investments sold 544 Candel Therapeutics shares in Q2 2026, an estimated $4.11K.
  • Candel Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1416 holding.
  • Mirae Asset Global Investments first reported a position in Candel Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 46 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.